Clinical Scorecard: Impact of Aggressive Hypertension Management on Cardiovascular Outcomes in Middle-Aged and Older Americans with High Blood Pressure

At a Glance

Key Highlights

• Intensive SBP treatment reduced cardiovascular events with a hazard ratio of 0.76 compared to standard treatment in the target population.
• No significant increase in serious adverse events was observed with intensive treatment (HR 0.97).
• SPRINT trial participants differ demographically and clinically from the general US hypertensive population, but benefits of intensive treatment generalize.

Guideline-Based Recommendations

Diagnosis

• Identify adults aged ≥50 years with SBP between 130 and 180 mm Hg and elevated cardiovascular risk (clinical/subclinical CVD, CKD, Framingham risk ≥15%, or age ≥75).
• Exclude patients with diabetes mellitus or history of stroke from intensive treatment consideration.

Management

• Intensive antihypertensive treatment targeting SBP <120 mm Hg is recommended to reduce cardiovascular events in eligible patients.
• Standard treatment targets SBP <140 mm Hg if intensive treatment is contraindicated or not tolerated.
• Preferred medications include thiazide diuretics and β-adrenergic blockers; lifestyle modifications such as sodium reduction are encouraged.

Monitoring & Follow-up

• Regular blood pressure monitoring to achieve and maintain target SBP levels.
• Monitor for adverse events including syncope and drug interactions, especially in older adults with comorbidities and polypharmacy.

Risks

• Potential adverse events from intensive treatment include syncope and drug–drug interactions.
• No significant increase in serious adverse events was observed in the studied population.

Patient & Prescribing Data

Middle-aged and older adults (≥50 years) with hypertension and elevated cardiovascular risk without diabetes or stroke.

Intensive SBP lowering to <120 mm Hg reduces cardiovascular events without increasing serious adverse events, supporting its use in eligible patients.

Clinical Best Practices

• Screen and identify patients meeting SPRINT eligibility criteria for intensive blood pressure management.
• Use individualized treatment plans incorporating preferred antihypertensive agents and lifestyle changes.
• Educate patients on the benefits and potential risks of intensive blood pressure control.
• Monitor patients closely for efficacy and adverse events, adjusting therapy as needed.

References

• SPRINT Trial Primary Publication
• National Health and Nutrition Examination Survey (NHANES)